ReviewActa parasitologica2021
The Association Between the Syrian Crisis and Cutaneous Leishmaniasis in Lebanon.
Review in Acta parasitologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Vector-borne diseases and the Syrian conflict: A systematic review of literature from Syria and neighbouring, refugee-hosting countries.PLoS neglected tropical diseases · 2025Pooled it
- Refugees/Immigrants and leishmaniasis in the world's largest hosting country, Türkiye: A systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Quality of life and patient satisfaction among individuals with cutaneous leishmaniasis in Syria: a cross-sectional study.Infectious diseases of poverty · 2026Article
- The Burden of Skin and Subcutaneous Diseases in North Africa and the Middle East (NAME) From 1990 to 2021.International journal of dermatology · 2025Article
- A multifaceted molecular approach to surveillance of leishmaniasis: Identification of sand fly species, Leishmania parasites, and blood meal sources using high-resolution melting analysis.PLoS neglected tropical diseases · 2025Article
- Structural Drivers of Cutaneous Leishmaniasis: Examining How the Converging Effects of Displacement, Environmental Disruption, and Political Instability Reshape Epidemiology Beyond Endemic Regions.Tropical medicine and infectious disease · 2025Review
- New insights into the life cycle, host cell tropism, and infection amplification ofInfection and immunity · 2025Review
- Cutaneous Leishmaniasis in the Context of Global Travel, Migration, Refugee Populations, and Humanitarian Crises.Clinics and practice · 2025Review
- Molecular diagnosis and epidemiological aspects of cutaneous Leishmaniasis in Aleppo: Current status.Parasite epidemiology and control · 2025Article
- Evaluation of Beauvericin's activity and mode of action against all life stages ofFrontiers in cellular and infection microbiology · 2025Article
- Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis.Journal of epidemiology and global health · 2024Review
- The Possible Role of Selected Vitamins and Minerals in the Therapeutic Outcomes of Leishmaniasis.Biological trace element research · 2023Review
- An Update on the Imported Cutaneous Leishmaniasis in Europe.Infectious diseases & clinical microbiology · 2023Article
- Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan.Frontiers in public health · 2023Review
- Cutaneous leishmaniasis in Tabuk, Saudi Arabia: epidemiological trends from 2006 to 2021.The Pan African medical journal · 2023Article
- Impact of wars and natural disasters on emerging and re-emerging infectious diseases.Frontiers in public health · 2023Review
- Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.Pathogens (Basel, Switzerland) · 2022Review
- Leishmaniasis: Recent epidemiological studies in the Middle East.Frontiers in microbiology · 2022Review
- HAS 1: A natural product from soil-isolatedFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDisplacement of refugees from highly endemic areas of leishmaniasis to adjacent countries is associated with the spread of Leishmania. Syria is a country with a known high endemicity for cutaneous leishmaniasis and the presence of Syrian refugees in Lebanon has contributed to the re-emergence of the disease. The aim of this article is to evaluate the burden of cutaneous leishmaniasis in Lebanon in view of the presence of a large number of Syrian refugees.
methodsData regarding all cases of leishmaniasis were collected from reports by the Lebanese Ministry of Public Health-Epidemiology Surveillance (LMPH-ESU), and the World Health Organization (WHO) between 2005 and 2018. All cases were reviewed in terms of area of residence, age and gender, clinical presentation, treatment, and outcome. An extensive literature review was conducted using "PubMed", "Medline", and "Google Scholar".
resultsThe annual number of leishmaniasis cases recorded in Lebanon between 2005 and 2011 ranged between 0 and 6 cases. In 2012, this number increased to 1275 cases and dropped to 263 in 2018, where all those infected were Syrian refugees from Aleppo, with zero cases of local transmission. Seventy-two percent of cases were seen in patients aged < 20 years. The predominant species of Leishmania was L. tropica followed by L. major.
conclusionLebanon was affected by leishmaniasis following the Syrian crisis, and the influx of refugees to the country. Accurate disease monitoring and strategic training of healthcare personnel based within refugee camps are essential for proper containment. Preventative measures remain the best way to avoid both local and adjacent spread of leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.